177 related articles for article (PubMed ID: 22834902)
1. Discovery of a novel noniminosugar acid α glucosidase chaperone series.
Xiao J; Westbroek W; Motabar O; Lea WA; Hu X; Velayati A; Zheng W; Southall N; Gustafson AM; Goldin E; Sidransky E; Liu K; Simeonov A; Tamargo RJ; Ribes A; Matalonga L; Ferrer M; Marugan JJ
J Med Chem; 2012 Sep; 55(17):7546-59. PubMed ID: 22834902
[TBL] [Abstract][Full Text] [Related]
2. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
[TBL] [Abstract][Full Text] [Related]
3. Systematic structure-activity study on potential chaperone lead compounds for acid α-glucosidase.
Bruckmann C; Repo H; Kuokkanen E; Xhaard H; Heikinheimo P
ChemMedChem; 2012 Nov; 7(11):1943-53. PubMed ID: 22969039
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological enhancement of α-glucosidase by the allosteric chaperone N-acetylcysteine.
Porto C; Ferrara MC; Meli M; Acampora E; Avolio V; Rosa M; Cobucci-Ponzano B; Colombo G; Moracci M; Andria G; Parenti G
Mol Ther; 2012 Dec; 20(12):2201-11. PubMed ID: 22990675
[TBL] [Abstract][Full Text] [Related]
5. A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease.
Han SO; Pope R; Li S; Kishnani PS; Steet R; Koeberl DD
Mol Genet Metab; 2016 Feb; 117(2):114-9. PubMed ID: 26454691
[TBL] [Abstract][Full Text] [Related]
6. Moss-Derived Human Recombinant GAA Provides an Optimized Enzyme Uptake in Differentiated Human Muscle Cells of Pompe Disease.
Hintze S; Limmer S; Dabrowska-Schlepp P; Berg B; Krieghoff N; Busch A; Schaaf A; Meinke P; Schoser B
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290314
[TBL] [Abstract][Full Text] [Related]
7. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
Kishnani PS; Beckemeyer AA
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
[TBL] [Abstract][Full Text] [Related]
8. The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase.
Flanagan JJ; Rossi B; Tang K; Wu X; Mascioli K; Donaudy F; Tuzzi MR; Fontana F; Cubellis MV; Porto C; Benjamin E; Lockhart DJ; Valenzano KJ; Andria G; Parenti G; Do HV
Hum Mutat; 2009 Dec; 30(12):1683-92. PubMed ID: 19862843
[TBL] [Abstract][Full Text] [Related]
9. Improved efficacy of a next-generation ERT in murine Pompe disease.
Xu S; Lun Y; Frascella M; Garcia A; Soska R; Nair A; Ponery AS; Schilling A; Feng J; Tuske S; Valle MCD; Martina JA; Ralston E; Gotschall R; Valenzano KJ; Puertollano R; Do HV; Raben N; Khanna R
JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843882
[TBL] [Abstract][Full Text] [Related]
10. Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease.
Cousens LP; Mingozzi F; van der Marel S; Su Y; Garman R; Ferreira V; Martin W; Scott DW; De Groot AS
Hum Vaccin Immunother; 2012 Oct; 8(10):1459-64. PubMed ID: 23095864
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Chaperone Therapy for Pompe Disease.
Borie-Guichot M; Tran ML; Génisson Y; Ballereau S; Dehoux C
Molecules; 2021 Nov; 26(23):. PubMed ID: 34885805
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease.
Parenti G; Zuppaldi A; Gabriela Pittis M; Rosaria Tuzzi M; Annunziata I; Meroni G; Porto C; Donaudy F; Rossi B; Rossi M; Filocamo M; Donati A; Bembi B; Ballabio A; Andria G
Mol Ther; 2007 Mar; 15(3):508-14. PubMed ID: 17213836
[TBL] [Abstract][Full Text] [Related]
13. Avalglucosidase alfa: First Approval.
Dhillon S
Drugs; 2021 Oct; 81(15):1803-1809. PubMed ID: 34591286
[TBL] [Abstract][Full Text] [Related]
14. Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice.
Su J; Sherman A; Doerfler PA; Byrne BJ; Herzog RW; Daniell H
Plant Biotechnol J; 2015 Oct; 13(8):1023-32. PubMed ID: 26053072
[TBL] [Abstract][Full Text] [Related]
15. Enhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders.
Hsu J; Northrup L; Bhowmick T; Muro S
Nanomedicine; 2012 Jul; 8(5):731-9. PubMed ID: 21906578
[TBL] [Abstract][Full Text] [Related]
16. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
Wang Z; Okamoto P; Keutzer J
Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
[TBL] [Abstract][Full Text] [Related]
17. Akt inactivation induces endoplasmic reticulum stress-independent autophagy in fibroblasts from patients with Pompe disease.
Nishiyama Y; Shimada Y; Yokoi T; Kobayashi H; Higuchi T; Eto Y; Ida H; Ohashi T
Mol Genet Metab; 2012 Nov; 107(3):490-5. PubMed ID: 23041259
[TBL] [Abstract][Full Text] [Related]
18. The pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe disease.
Khanna R; Powe AC; Lun Y; Soska R; Feng J; Dhulipala R; Frascella M; Garcia A; Pellegrino LJ; Xu S; Brignol N; Toth MJ; Do HV; Lockhart DJ; Wustman BA; Valenzano KJ
PLoS One; 2014; 9(7):e102092. PubMed ID: 25036864
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and structural study on a S529V mutant acid α-glucosidase responsive to pharmacological chaperones.
Tajima Y; Saito S; Ohno K; Tsukimura T; Tsujino S; Sakuraba H
J Hum Genet; 2011 Jun; 56(6):440-6. PubMed ID: 21471980
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
